Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT06704620 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06704620
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-01
- Primary completion
- 2026-11-01
- Enrollment
- 430
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.